Summary First-Mover Advantage: Soleno has the market to itself until competition intensifies. High Sales Potential: Projected sales of $876 million by 2030 are highly attractive. Commercial Challenges:...
VYKAT XR has now been delivered to the first individuals living with PWS who have been prescribed the medication, the company said.
Summary First-Mover Advantage: Soleno has the market to itself until competition intensifies. High Sales Potential: Projected sales of $876 million by 2030 are highly attractive. Commercial Challenges:...
Despite weak economic data, the S&P 500 (SPX) closed higher to start the new quarter, as traders await President Donald Trump’s tariff policy rollout. In the face of financial turbulence, several promising...